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Antigen-presenting cells (APCs) are 
critical to the initiation and tuning of 
T-cell responses. Georg Stingl (Medical 
University of Vienna, Austria) described 
three types of APCs in the skin. Studies 
on genetically modified mice suggest 
that epidermal Langerhans cells sup-
press T-cell responses and promote 
tolerance, contrary to earlier reports. 
Dermal DCs, on the other hand, elicit 
potent immune reactions when antigen 
is taken up under conditions that induce 
DC maturation. pDCs are scarce in nor-
mal skin, frequent in inflamed skin, 
and, together with a subtype of mye loid 
DCs, accumulate in imiquimod-treated 
skin. Both imiquimod-induced myeloid 
DCs and pDCs express molecules of 
the lytic machinery, kill cancer cells 
in vitro, and may be responsible for 
imiquimod-induced regression in basal 
cell carcinomas (BCCs). Based on recent 
evidence, Stingl and his co-workers 
propose that TLR7-activated pDCs may 
contribute to the apoptotic death of 
activated T cells in HIV infection.
APCs and other cells sense patho-
gens via TLRs, a set of pathogen recep-
tors hard-wired into the genome. 
Michael Schön (Georg August 
University, Germany) described how 
these highly conserved receptors signal 
through MyD88, and have a common 
double-arched shape despite the differ-
ing structures of their ligands. TLRs can 
induce both stimulatory and inhibitory 
signals, and TLR signaling contributes 
to autoimmune diseases, including 
lupus erythematosus and inflammato-
ry bowel disease. Stimulation of TLR9 
from the apical surface of intestinal 
cells downmodulates inflammatory 
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was held in Boston, Massachusetts.* 
Ninety-eight physicians and scien-
tists from 13 countries attended. 
Organized by Robert Fuhlbrigge and 
Rachael Clark (Harvard University, 
Boston, MA), the course covered the 
latest developments in cutaneous 
immunology. Thomas Kupper (Harvard 
University) began by quoting Albert 
Szent-Györgyi: “Discovery is see-
ing what everybody else has seen, 
and thinking what nobody else has 
thought.”
Michael Zasloff (Georgetown Uni-
versity, Washington, DC) presented a 
fascinating overview of anti microbial 
peptides (AMPs), small proteins 
produced by epithelial cells that pro-
vide front-line protection against skin 
pathogens. The AMP repertoire varies at 
different body sites and reflects differ-
ing skin flora at these sites. Vitamin D 
induces production of the AMP LL-37, 
and this molecule, together with Toll-
like receptor (TLR) activation, enhances 
the ability of macrophages to kill myco-
bacteria. The underproduction and 
overproduction of AMP are associated 
with human diseases. Atopic dermatitis 
patients have decreased levels of AMP 
and frequent skin infections. AMPs are 
overproduced in psoriatic skin, and 
individuals with increased copy num-
bers of β-defensin AMP genes are at 
increased risk for developing the dis-
ease. A complex of self-DNA and LL-37 
stimulates activation of plasmacytoid 
dendritic cells (pDCs), a critical event 
in the initiation of psoriatic lesions.
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NFκβ signaling, but stimulation from 
the basal surface is proinflammatory. 
TLR7/8 agonists such as imiquimod 
are used to treat actinic keratoses and 
BCC; Schön showed striking photos 
of cutaneous metastases of malignant 
melanoma that cleared after topi-
cal imiquimod therapy. In addition to 
TLR7/8 signaling, imiquimod can acti-
vate cells via adenosine receptors and 
can induce tumor cell death directly.
DCs travel to lymph nodes, where 
they present antigens to T and B cells. 
Using intravital microscopy in anes-
thetized mice, Ulrich Von Andrian 
(Harvard University) observed that 
T cells interacting with antigen-laden 
DCs progressed through three stag-
es. They first made brief serial con-
tacts with many DCs and became 
activated. They then formed stable, 
long-lasting contacts with a single 
DC and developed cytokine produc-
tion and effector functions. Finally, 
they again made brief contacts with 
multiple DCs and proliferated. These 
stages—dating, mating, and procreat-
ing—allowed T cells to scan multiple 
DCs and integrate these signals into 
a single decision to respond or not. 
Von Andrian also reported that macro-
phages present in the subcapsular 
sinus of lymph nodes trap particulates, 
including viruses, and then present 
these particles to lymph node B cells.
Regulatory T (Treg) cells and IL-17-
producing T helper (Th17) cells are 
two recently described T-cell subsets 
with reciprocal roles. Treg cells induce 
and maintain self-tolerance. Th17 cells 
not only defend against extra cellular 
pathogens but also contribute to 
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inflammatory diseases such as arthritis 
and psoriasis. Estelle Bettelli (Harvard 
University) presented studies of experi-
mental autoimmune encephalomyelitis 
in mice, a Th17- and Th1-mediated dis-
ease. IL-6 promoted Th17 development 
and inhibited formation of Treg cells. 
Transforming growth factor-β (TGF-β), 
IL-21, and IL-23 also drove pathogenic 
Th17 cells. Similar findings have been 
reported in psoriasis. DCs and kerati-
nocytes in psoriatic lesions overpro-
duce IL-23, driving the development 
and proliferation of Th17 cells. These 
cells, in turn, produce IL-22 and other 
inflammatory mediators. IL-22 induces 
keratinocyte proliferation and acantho-
sis in the epidermis. These studies sug-
gest that interruption of IL-23 signaling 
or Th17 effector function might benefit 
patients with any of several different 
inflammatory disorders.
Few topics have received more 
attention recently than vitamin D. 
Several studies show that the major-
ity of people in the United States are 
vitamin D deficient, especially in win-
ter. Dermatologists must walk a fine 
line in recommending sun protection 
for vulnerable patients while ensuring 
that they obtain adequate vitamin D. 
Daniel Bikle (University of California, 
San Francisco) spoke about recent 
findings that vitamin D plays a critical 
role in immune responses. It stimulates 
the production of AMPs by skin, and, 
upon stimulation, macrophages can 
generate their own vitamin D, enhanc-
ing their ability to kill pathogens. 
Vitamin D also promotes the differenti-
ation of Th2 and Treg cells, inhibits the 
differentiation of Th17 cells, and helps 
to imprint T cells with skin-homing 
addressins. Recent studies suggest that 
2,000 units of vitamin D per day may 
be required to obtain adequate blood 
levels, but optimal dosage varies from 
patient to patient.
Hilde Cheroutre (La Jolla Institute 
for Allergy and Immunology, San 
Diego, CA) presented evidence that 
retinoic acid (RA), a derivative of 
vitamin A, plays a critical role in gas-
trointestinal immunity. RA produced 
by gut DCs induces T-cell expression 
of gut-homing addressins. RA pro-
motes the development of Treg cells, 
suppresses IL-17 production, and, 
together with TGF-β, can repolarize 
Th17 cells to a regulatory phenotype. 
Thus, under normal conditions, RA 
helps to drive T-cell immunity toward 
the formation of tolero genic Treg cells. 
In mice, a population of CD4 T cells 
coexpresses CD8αα after exposure 
to the gut microenvironment. Under 
normal conditions, the activity of 
these cells is suppressed, but CD8αα 
T cells can become highly cytotoxic 
when exposed to inflammation. Thus, 
reprogramming at peripheral tissue 
sites supports the generation of tole-
rogenic T cells at baseline, but mecha-
nisms exist that allow these T cells to 
become highly cytotoxic if necessary.
In his keynote address, David Altshuler 
(Harvard University) described how 
genome-wide genetic mapping allows 
the linkage of disease states to genetic 
alleles expressed by affected individu-
als. Technology-driven improvements 
have allowed a shift from hypoth-
esis testing to hypothesis genera-
tion. Instead of confirming the role of 
previously identified gene products, 
these screens allow the identification 
of previously unsuspected molecules 
that can then be tested as drug targets. 
Small population variations in a clinical 
measurement can allow the identifica-
tion of gene products that, if inhibited 
completely, may have a substantial 
clinical effect, because population 
studies determine the effect of a par-
ticular allele on a clinical parameter, 
not the effect of complete inhibition of 
a particular gene product. New devel-
opments in sequencing technology are 
expected to rapidly increase the scope 
and power of these approaches.
Jiali Han (Harvard University) pre-
sented his work on genome-wide 
genetic mapping of polymorphisms 
conferring susceptibility to skin can-
cer. Han gathered data from the 
Nurses Health Study, a cohort of over 
120,000 women followed since 1976. 
Risk-factor data were collected prior to 
disease development. Blood samples 
from women who developed skin can-
cer were compared with age-matched 
controls. Polymorphisms in the MC1R 
gene associated with pheomelanin 
(red hair) conferred increased risk for 
both melanoma and nonmelanoma 
skin cancers, and MC1R variants 
helped the researchers predict the 
development of melanoma and BCC in 
other patient populations. Han’s work 
illustrates how genome-wide genetic 
mapping can be used both to study the 
underlying biology of a disease and to 
predict disease development in patient 
populations.
Gregory Lanza (Washington Uni-
versity, St. Louis, MO) described his 
cutting-edge work with fluoro carbon 
nanoparticles. Highly visible by MRI 
or ultrasound, proteins can be added 
to target these particles specifically 
(for instance, to areas of angiogenesis 
in tumors or sites of inflammation). 
Medications can also be incorporated 
and delivered directly to targeted cells. 
Specifically, αvβ3-integrin targeted 
nanoparticles filled with the angio-
genesis inhibitor fumagillin inhibited 
angiogenesis in rabbit breast cancers 
and clinically improved arthritis in 
mouse models. Nanoparticles can be 
used to visualize angiogenesis, inhibit 
it, and then monitor responses to ther-
apy. Lanza described photo acoustic 
tomography, a new technology in 
which a laser pulse excites skin or 
another tissue and the resultant vibra-
tions are detected by ultrasound. Using 
gadolinium-enhanced nanoparticles, 
this method allowed noninvasive sen-
tinel lymph node mapping in rats and 
has many promising dermatological 
applications.
Psoriasis and atopic dermatitis, two 
common inflammatory skin diseases, 
were addressed next. Brian Nickoloff 
(Loyola University, Chicago, IL) dis-
cussed the changing focus of psoriasis 
research. Initially focused solely on 
keratinocytes, psoriasis researchers now 
understand that plasmacytoid DCs and 
Th17 T cells play a critical role in the 
pathogenesis of this disease. Thomas 
Bieber (University of Bonn, Germany) 
presented an elegant discussion of 
atopic dermatitis (AD) with an empha-
sis on personalized medicine. AD is 
a clinically and genetically hetero-
geneous disease. Genes predisposing 
to AD fall into two broad categories: 
skin-related genes that affect barrier 
function and atopy-related genes that 
affect the tendency of an individual 
to be allergic. Polymorphisms in the 
filaggrin gene that impair skin barrier 
RA Clark and RC Fuhlbrigge
Immunology and Skin Disease 2009: Frontiers in Cutaneous Immunology
 www.jidonline.org 1851
function and changes in the gene for 
IL-4 and its receptor are all associated 
with AD. Knowledge of an individual’s 
risk alleles could be used to tailor ther-
apy and to identify individuals at risk 
for progressive sensitization, allow-
ing early intervention to improve bar-
rier function. Epigenetic changes may 
explain why some individuals develop 
AD later in life, and the environment 
also plays a critical role. AD skin 
shows residual signs of inflammation 
even between flares. Proactive inter-
mittent use of steroids or calcineurin 
inhibitors significantly decreases both 
the frequency and severity of flares.
Rachael Clark (Harvard University) 
noted that a minority of patients with 
cutaneous T-cell lymphoma (CTCL) 
develop rapid and fatal disease 
progression. Differentiating these high-
risk patients from the majority who 
do well is difficult. Clonal T cells with 
chromosomal abnormalities are pres-
ent in both early and advanced CTCL, 
suggesting that genetic damage is a 
common feature. Marked loss of T-cell 
diversity often occurs, indicating wide-
spread T-cell death on a par with HIV 
disease. Neutrophils are activated, and 
Staphylococcus aureus–driven inflam-
mation of T cells worsens the disease. 
Extracorporeal photopheresis improves 
CTCL, but evidence suggests that it does 
so by inducing tolerance. New findings 
in skin T-cell biology explain some but 
not all features of the disease, and a 
unifying hypothesis remains elusive.
Smallpox vaccination, which inv-
olves scarification of the skin, is the 
most effective vaccination in record-
ed history. Luzheng Liu (Harvard 
University) described studies showing 
that scarification provided enhanced 
systemic immunity and protection 
against skin and respiratory chal-
lenge in vaccinia-immunized mice. 
Following scarification, T cells entered 
the skin-draining lymph node and 
generated effector cells express-
ing skin-homing receptors. Early on, 
antigen-specific cells also seeded 
other lymph nodes and gave rise to 
additional effector populations able 
to access other tissues. Liu’s work sug-
gests that scarification is a safe and 
highly effective vaccination route 
capable of inducing potent and widely 
disseminated immune protection.
James Campbell (Harvard University) 
described his work on T-cell homing 
to skin in mice. He pointed out that 
a T cell’s homing receptor expression 
should be considered separately from 
its functional characteristics because 
the chemokine profile of a T cell indi-
cates its homing characteristics but 
does not define its functional differen-
tiation (e.g., Th17). Recent studies have 
shown that immunization via the skin 
gave rise to T cells with skin-homing 
phenotypes, whereas immunization 
through the gut generated gut-homing 
T cells. CCR4 is a chemokine recep-
tor expressed by T cells in human and 
mouse skin, but it is also expressed by 
noncutaneous T cells. This raises the 
question of whether CCR4 functions as 
a skin-homing receptor. Using CCR4-
deficient mice, Campbell demonstrat-
ed that CCR4 plays a critical role in 
supporting T-cell entry into the skin.
The meeting concluded with a 
fascinating presentation by Robert 
Sackstein (Harvard University) on mes-
enchymal stem cells (MSCs). In con-
trast to embryonic stem cells, MSCs 
can be obtained from adult bone mar-
row and do not form teratomas. MSCs 
have many natural functions, includ-
ing the formation of vascular pericytes. 
They can also enhance tissue repair 
and are markedly immuno suppressive. 
MSCs secrete nitric oxide, produce 
indolamine 2, 3-dioxygenase and 
prostaglandin E2, and suppress mixed 
leuko cyte reactions. MSCs from unre-
lated donors can halt the progression 
of severe graft-versus-host disease in 
critically ill patients. By inducing the 
formation of the carbohydrate HCELL 
on cell surfaces, Sackstein targeted 
intra venously infused MSCs to the bone 
marrow with the goal of enhancing 
bone production, a possible treatment 
for osteoporosis.
Fuhlbrigge concluded the course 
with thanks to the organizers, speak-
ers, and attendees.
* Immunology and Skin Disease 2009: Frontiers in 
Cutaneous Immunology was held at the Fairmont 
Copley Plaza Hotel in Boston, Massachusetts, 
USA, 19–21 March 2009.
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